Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer

Paraneoplastic encephalomyelitis (PEM) is a form of neurological dysfunction caused by the remote effect of small cell lung cancer (SCLC) on the brain. In certain cases it is associated with the presence of Anti-Hu antibodies. Up to 65% of patients with SCLC and PEM, who have Anti-Hu antibodies pres...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Palliative medicine 2003-10, Vol.17 (7), p.638-639
Hauptverfasser: Douglas, Claire A, Ellershaw, John
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 639
container_issue 7
container_start_page 638
container_title Palliative medicine
container_volume 17
creator Douglas, Claire A
Ellershaw, John
description Paraneoplastic encephalomyelitis (PEM) is a form of neurological dysfunction caused by the remote effect of small cell lung cancer (SCLC) on the brain. In certain cases it is associated with the presence of Anti-Hu antibodies. Up to 65% of patients with SCLC and PEM, who have Anti-Hu antibodies present, die of neurological complications rather than tumour progression. Chemotherapy is not believed to be beneficial. We describe a 58-year-old lady who was bed-bound and significantly disabled from paraneoplastic cerebellar degeneration. Her serology confirmed the presence of Anti-Hu antibodies and SCLC was confirmed at bronchoscopy. Following six courses of chemotherapy her neurological symptoms have remarkably improved, both subjectively and objectively, such that she is now independently mobile with a walking frame. Her tumour is still evident on bronchoscopy. We suggest that people with SCLC who are significantly disabled by neurological symptoms, should be tested for serum anti-neuronal antibodies and if Anti-Hu antibody positive, anti-neoplastic treatment should be considered despite poor performance status.
doi_str_mv 10.1191/0269216303pm758cr
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71339285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1191_0269216303pm758cr</sage_id><sourcerecordid>71339285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-697f8f9b694f0d95627222d1e87f8a89a349d10e72ba9a248ac2e56bbd81a6413</originalsourceid><addsrcrecordid>eNqFkU-L1TAUxYMozpvRD-BGguDsOuYmaf4sh0EdYcCNgrtym6YzGdqmJu3A2_rJTXkPHijiJheS37n35B5C3gC7ArDwgXFlOSjBxDzq2rj0jOxAal0xwX48J7vtvdqAM3Ke8yNjIJiSL8kZyNpKqNWO_LqellDdrhRLbWMXfKYj7mmYuuBw8RTpHHNYwpOnyec5TtnTJVL34Me4PPiE8wbTGRNOPs4D5iU4mvdTl-LoafYuTh2m_SbKIw4Ddb4cwzrdU4eT8-kVedHjkP3rY70g3z99_HZzW919_fzl5vquctKypVJW96a3rbKyZ52tFdec8w68KfdoLAppO2Be8xYtcmnQcV-rtu0MoJIgLsjloe-c4s_V56UZQ97MbMbX3GgQwnJT_xesNTPSgi7guz_Ax7imqXyi4aCN4AxkgeAAuRRzTr5v5hTGspEGWLPF2PwVY9G8PTZe29F3J8UxtwK8PwKYHQ59Wb4L-cTVYISypnBXBy7jvT-5-_fk3xAVtXg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217832014</pqid></control><display><type>article</type><title>Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>MEDLINE</source><source>SAGE Complete</source><creator>Douglas, Claire A ; Ellershaw, John</creator><creatorcontrib>Douglas, Claire A ; Ellershaw, John</creatorcontrib><description>Paraneoplastic encephalomyelitis (PEM) is a form of neurological dysfunction caused by the remote effect of small cell lung cancer (SCLC) on the brain. In certain cases it is associated with the presence of Anti-Hu antibodies. Up to 65% of patients with SCLC and PEM, who have Anti-Hu antibodies present, die of neurological complications rather than tumour progression. Chemotherapy is not believed to be beneficial. We describe a 58-year-old lady who was bed-bound and significantly disabled from paraneoplastic cerebellar degeneration. Her serology confirmed the presence of Anti-Hu antibodies and SCLC was confirmed at bronchoscopy. Following six courses of chemotherapy her neurological symptoms have remarkably improved, both subjectively and objectively, such that she is now independently mobile with a walking frame. Her tumour is still evident on bronchoscopy. We suggest that people with SCLC who are significantly disabled by neurological symptoms, should be tested for serum anti-neuronal antibodies and if Anti-Hu antibody positive, anti-neoplastic treatment should be considered despite poor performance status.</description><identifier>ISSN: 0269-2163</identifier><identifier>EISSN: 1477-030X</identifier><identifier>DOI: 10.1191/0269216303pm758cr</identifier><identifier>PMID: 14594156</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Autoantibodies - blood ; Biological and medical sciences ; Biomarkers - blood ; Carcinoma, Small Cell - drug therapy ; Carcinoma, Small Cell - immunology ; Chemotherapy ; ELAV Proteins ; Female ; Humans ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - immunology ; Medical sciences ; Middle Aged ; Nerve Tissue Proteins - immunology ; Neurological disorders ; Paraneoplastic Syndromes, Nervous System - drug therapy ; Paraneoplastic Syndromes, Nervous System - immunology ; Patient Selection ; Pharmacology. Drug treatments ; RNA-Binding Proteins - immunology ; Treatment Outcome ; Women</subject><ispartof>Palliative medicine, 2003-10, Vol.17 (7), p.638-639</ispartof><rights>2004 INIST-CNRS</rights><rights>2003 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-697f8f9b694f0d95627222d1e87f8a89a349d10e72ba9a248ac2e56bbd81a6413</citedby><cites>FETCH-LOGICAL-c490t-697f8f9b694f0d95627222d1e87f8a89a349d10e72ba9a248ac2e56bbd81a6413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1191/0269216303pm758cr$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1191/0269216303pm758cr$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,12825,21798,27901,27902,30976,30977,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15183698$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14594156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Douglas, Claire A</creatorcontrib><creatorcontrib>Ellershaw, John</creatorcontrib><title>Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer</title><title>Palliative medicine</title><addtitle>Palliat Med</addtitle><description>Paraneoplastic encephalomyelitis (PEM) is a form of neurological dysfunction caused by the remote effect of small cell lung cancer (SCLC) on the brain. In certain cases it is associated with the presence of Anti-Hu antibodies. Up to 65% of patients with SCLC and PEM, who have Anti-Hu antibodies present, die of neurological complications rather than tumour progression. Chemotherapy is not believed to be beneficial. We describe a 58-year-old lady who was bed-bound and significantly disabled from paraneoplastic cerebellar degeneration. Her serology confirmed the presence of Anti-Hu antibodies and SCLC was confirmed at bronchoscopy. Following six courses of chemotherapy her neurological symptoms have remarkably improved, both subjectively and objectively, such that she is now independently mobile with a walking frame. Her tumour is still evident on bronchoscopy. We suggest that people with SCLC who are significantly disabled by neurological symptoms, should be tested for serum anti-neuronal antibodies and if Anti-Hu antibody positive, anti-neoplastic treatment should be considered despite poor performance status.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Autoantibodies - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>Carcinoma, Small Cell - immunology</subject><subject>Chemotherapy</subject><subject>ELAV Proteins</subject><subject>Female</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - immunology</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nerve Tissue Proteins - immunology</subject><subject>Neurological disorders</subject><subject>Paraneoplastic Syndromes, Nervous System - drug therapy</subject><subject>Paraneoplastic Syndromes, Nervous System - immunology</subject><subject>Patient Selection</subject><subject>Pharmacology. Drug treatments</subject><subject>RNA-Binding Proteins - immunology</subject><subject>Treatment Outcome</subject><subject>Women</subject><issn>0269-2163</issn><issn>1477-030X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkU-L1TAUxYMozpvRD-BGguDsOuYmaf4sh0EdYcCNgrtym6YzGdqmJu3A2_rJTXkPHijiJheS37n35B5C3gC7ArDwgXFlOSjBxDzq2rj0jOxAal0xwX48J7vtvdqAM3Ke8yNjIJiSL8kZyNpKqNWO_LqellDdrhRLbWMXfKYj7mmYuuBw8RTpHHNYwpOnyec5TtnTJVL34Me4PPiE8wbTGRNOPs4D5iU4mvdTl-LoafYuTh2m_SbKIw4Ddb4cwzrdU4eT8-kVedHjkP3rY70g3z99_HZzW919_fzl5vquctKypVJW96a3rbKyZ52tFdec8w68KfdoLAppO2Be8xYtcmnQcV-rtu0MoJIgLsjloe-c4s_V56UZQ97MbMbX3GgQwnJT_xesNTPSgi7guz_Ax7imqXyi4aCN4AxkgeAAuRRzTr5v5hTGspEGWLPF2PwVY9G8PTZe29F3J8UxtwK8PwKYHQ59Wb4L-cTVYISypnBXBy7jvT-5-_fk3xAVtXg</recordid><startdate>200310</startdate><enddate>200310</enddate><creator>Douglas, Claire A</creator><creator>Ellershaw, John</creator><general>SAGE Publications</general><general>Turpin</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200310</creationdate><title>Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer</title><author>Douglas, Claire A ; Ellershaw, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-697f8f9b694f0d95627222d1e87f8a89a349d10e72ba9a248ac2e56bbd81a6413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Autoantibodies - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>Carcinoma, Small Cell - immunology</topic><topic>Chemotherapy</topic><topic>ELAV Proteins</topic><topic>Female</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - immunology</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nerve Tissue Proteins - immunology</topic><topic>Neurological disorders</topic><topic>Paraneoplastic Syndromes, Nervous System - drug therapy</topic><topic>Paraneoplastic Syndromes, Nervous System - immunology</topic><topic>Patient Selection</topic><topic>Pharmacology. Drug treatments</topic><topic>RNA-Binding Proteins - immunology</topic><topic>Treatment Outcome</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Douglas, Claire A</creatorcontrib><creatorcontrib>Ellershaw, John</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Sociology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Palliative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Douglas, Claire A</au><au>Ellershaw, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer</atitle><jtitle>Palliative medicine</jtitle><addtitle>Palliat Med</addtitle><date>2003-10</date><risdate>2003</risdate><volume>17</volume><issue>7</issue><spage>638</spage><epage>639</epage><pages>638-639</pages><issn>0269-2163</issn><eissn>1477-030X</eissn><abstract>Paraneoplastic encephalomyelitis (PEM) is a form of neurological dysfunction caused by the remote effect of small cell lung cancer (SCLC) on the brain. In certain cases it is associated with the presence of Anti-Hu antibodies. Up to 65% of patients with SCLC and PEM, who have Anti-Hu antibodies present, die of neurological complications rather than tumour progression. Chemotherapy is not believed to be beneficial. We describe a 58-year-old lady who was bed-bound and significantly disabled from paraneoplastic cerebellar degeneration. Her serology confirmed the presence of Anti-Hu antibodies and SCLC was confirmed at bronchoscopy. Following six courses of chemotherapy her neurological symptoms have remarkably improved, both subjectively and objectively, such that she is now independently mobile with a walking frame. Her tumour is still evident on bronchoscopy. We suggest that people with SCLC who are significantly disabled by neurological symptoms, should be tested for serum anti-neuronal antibodies and if Anti-Hu antibody positive, anti-neoplastic treatment should be considered despite poor performance status.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>14594156</pmid><doi>10.1191/0269216303pm758cr</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0269-2163
ispartof Palliative medicine, 2003-10, Vol.17 (7), p.638-639
issn 0269-2163
1477-030X
language eng
recordid cdi_proquest_miscellaneous_71339285
source Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; SAGE Complete
subjects Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autoantibodies - blood
Biological and medical sciences
Biomarkers - blood
Carcinoma, Small Cell - drug therapy
Carcinoma, Small Cell - immunology
Chemotherapy
ELAV Proteins
Female
Humans
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - immunology
Medical sciences
Middle Aged
Nerve Tissue Proteins - immunology
Neurological disorders
Paraneoplastic Syndromes, Nervous System - drug therapy
Paraneoplastic Syndromes, Nervous System - immunology
Patient Selection
Pharmacology. Drug treatments
RNA-Binding Proteins - immunology
Treatment Outcome
Women
title Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T09%3A57%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-Hu%20antibodies%20may%20indicate%20a%20positive%20response%20to%20chemotherapy%20in%20paraneoplastic%20syndrome%20secondary%20to%20small%20cell%20lung%20cancer&rft.jtitle=Palliative%20medicine&rft.au=Douglas,%20Claire%20A&rft.date=2003-10&rft.volume=17&rft.issue=7&rft.spage=638&rft.epage=639&rft.pages=638-639&rft.issn=0269-2163&rft.eissn=1477-030X&rft_id=info:doi/10.1191/0269216303pm758cr&rft_dat=%3Cproquest_cross%3E71339285%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217832014&rft_id=info:pmid/14594156&rft_sage_id=10.1191_0269216303pm758cr&rfr_iscdi=true